Appendix cancer medical therapy

Jump to navigation Jump to search

Appendix cancer Microchapters


Patient Information


Historical Perspective




Epidemiology and Demographics

Differentiating Appendix cancer from other Diseases

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings




CT scan

Echocardiography and Ultrasound

Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Appendix cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Appendix cancer medical therapy

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Appendix cancer medical therapy

CDC on Appendix cancer medical therapy

Appendix cancer medical therapy in the news

Blogs on Appendix cancer medical therapy

Directions to Hospitals Treating Appendix cancer

Risk calculators and risk factors for Appendix cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]


Medical therapy in appendix cancer could be either supportive, palliative, or curative. While carcinoid tumors rarely need chemotherapy, systemic chemotherapy as well as hyperthermic intraperitoneal chemotherapy plus/minus early postoperative intraperitoneal chemotherapy (EPIC) and/or concomitant intravenous chemotherapy are mainstream of medical treatment in adenocarcinoma of appendix. Medical therapy is generally administered to control the symptoms in patients with carcinoid tumors and carcinoid syndrome.

Medical Therapy

  • Supportive medical therapy for appendix cancer, may include:[1][2]
  • Curative and palliative chemotherapy
  • Systemic chemotherapy
  • Systemic chemotherapy has not been generally recommended for carcionid tumors, but patients with non-cacinoid tumors are usually receive chemotherapy.

Modified FOLFOX-6[4][5]
  • Dilute with 250 mL 5 percent dextrose in water (D5W)
  • Administer over 2 hrs
  • Avoid extravasation: May cause significant tissue damage
  • Dilute with 250 mL D5W
  • Administer over 2 hrs concurrent with oxaliplatin.
  • Slow IV push over 5 mins (administer immediately after leucovorin)
  • Administer immediately after FU IV bolus
  • Dilute with 500 to 1000 mL D5W
  • Administer over 46 hours
  • Cycle length is 14 days
  • Doses should be recalculated if there is a 10 percent or more change in body weight.
  • Prior to each treatment
  • Common complications and approaches to complications
  • Diarrhea:
  • In order to decrease chance of developing oxaliplatin induced neuropathy recommend patients to avoid exposure to cold up to 48 hours after each infusion.
  • Transient grade 3 paresthesia/dysesthesia / grade 2 symptoms lasting longer than 1 week:
  • Grade 4 or persistent grade 3 paresthesia/dysesthesia:
  • Total white blood cell count <3000 cells/mm 3 , absolute neutrophil count <1500 cells/mm 3 , or platelets <100,000 /mm 3 on the day of treatment:
    • Delay treatment cycle by one week.
  • If treatment is delayed for two weeks or delayed for one week on two separate occasions, eliminate FU bolus.
  • If occurred again:
  • Reduce infusional 5-FU by 20 percent and
  • Reduce oxaliplatin dose from 65 mg/m 2
  • Delivered in the operating room after cytoreductive surgery.
  • In selected cases is accompanied by early postoperative intraperitoneal chemotherapy (EPIC) as well as concomitant intravenous chemotherapy (CIVC).
Common HIPEC current regimens
  • Mitomycin C, 35 mg/m 2 for 90 minutes
  • Concomitant intravenous chemotherapy 5-FU, 400 mg/m 2
  • Early postoperative intraperitoneal chemotherapy (EPIC) with 5-FU
  • Mitomycin C, 35 mg/m 2 for 90 minutes without EPIC or CIVC
  • Mitomycin C, 3.3 mg//m 2/L for 90 minutes without EPIC or CIVC
  • Infuse the fluid at 43-45°Ci n order to maintain the intraperitoneal fluid temperature at 41-43°C.
  • To avoid renal toxicity maintain urine output higher than 100 cc (desirable 150 cc) every 15 min during HIPEC.


  1. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB (1987). "Carcinoid tumor of the appendix: treatment and prognosis". N. Engl. J. Med. 317 (27): 1699–701. doi:10.1056/NEJM198712313172704. PMID 3696178.
  2. Treatment Option Overview for GI Carcinoid Tumors . NATIONAL CANCER INSTITUTE . Accessed on September 22, 2015
  3. 3.0 3.1 González-Moreno S, González-Bayón LA, Ortega-Pérez G (2010) Hyperthermic intraperitoneal chemotherapy: Rationale and technique. World J Gastrointest Oncol 2 (2):68-75. DOI:10.4251/wjgo.v2.i2.68 PMID: 21160924
  4. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ et al. (2002) A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. Br J Cancer 87 (4):393-9. DOI:10.1038/sj.bjc.6600467 PMID: 12177775
  5. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26 (21):3523-9. DOI:10.1200/JCO.2007.15.4138 PMID: 18640933
  6. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2):229-37. DOI:10.1200/JCO.2004.05.113 PMID: 14657227

Template:WH Template:WS